ABSTRACT
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INTRODUCTION
The traditional approach to screening for pre-eclampsia (PE) is to identify risk factors from maternal demographic characteristics and medical history (maternal factors) 1, 2 . In the UK, the National Institute for Health and Care Excellence (NICE) has issued guidelines recommending that women should be considered to be at high risk of developing PE if they have any one high-risk factor or any two moderate-risk factors; high-risk factors are history of hypertensive disease in previous pregnancy, chronic kidney disease, autoimmune disease, diabetes mellitus or chronic hypertension and moderate-risk factors are first pregnancy, age ≥ 40 years, interpregnancy interval > 10 years, body mass index (BMI) at first visit of ≥ 35 kg/m 2 or family history of PE 1 . In the USA, according to the American College of Obstetricians and Gynecologists (ACOG), taking a medical history to evaluate for risk factors is currently the best and only recommended screening approach for PE; risk factors are nulliparity, age > 40 years, BMI ≥ 30 kg/m 2 , conception by in-vitro fertilization, history of previous pregnancy with PE, family history of PE, chronic hypertension, chronic renal disease, diabetes mellitus, systemic lupus erythematosus or thrombophilia 2 . Consequently, the approaches recommended by NICE and ACOG essentially treat each risk factor as a separate screening test, with additive detection rate (DR) and screen-positive rate. According to NICE, all high-risk pregnancies should be offered low-dose aspirin. According to ACOG, use of aspirin should be reserved for women with history of PE in two or more previous pregnancies or PE requiring delivery < 34 weeks' gestation 3 . An alternative approach to screening, developed by The Fetal Medicine Foundation (FMF), allows estimation of individual patient-specific risks of PE requiring delivery before a specified gestation, with the use of Bayes' theorem to combine the a-priori risk from maternal factors, derived by a multivariable logistic model, with the results of various combinations of biophysical and biochemical measurements 4, 5 . In a previous study, we used data from prospective screening in 35 948 singleton pregnancies at 11-13 weeks to develop an algorithm for the calculation of patient-specific risk of PE 5 . Combined screening by maternal factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) and serum placental growth factor (PlGF) achieved detection rates (DRs) of delivery with PE < 32, < 37 and ≥ 37 weeks of 89%, 75% and 47%, respectively, at a false-positive rate (FPR) of 10% 5 . A limitation of the study is that the performance of screening by a model derived and tested using the same dataset may be overestimated. However, a recent multicenter study in 8775 singleton pregnancies confirmed the validity of the algorithm and reported DRs of 100% (95% CI, 80-100%), 75% (95% CI, 62-85%) and 43% (95% CI, 35-50%) for PE delivering < 32, < 37 and ≥ 37 weeks, respectively, at a 10% FPR 6 . The objective of this study was to examine the performance of screening based on risk factors from medical history, as recommended by NICE 1 and ACOG 2,3 , using the method proposed by the FMF.
METHODS
This was a prospective, non-intervention, multicenter study in singleton pregnancies at 11 + 0 to 13 + 6 weeks' gestation in women booking for routine pregnancy care in one of 12 maternity hospitals in five different countries: King's College Hospital, London, UK; Medway Maritime Hospital, Gillingham, UK; Homerton University Hospital, London, UK; North Middlesex University Hospital, London, UK; Southend University Hospital, Essex, UK; Lewisham University Hospital, London, UK; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain; Hospital Universitario San Cecilio, Granada, Spain; Hospiten Sur, Tenerife, Spain; Centre Hospitalier Universitaire Brugmann, Brussels, Belgium; Attikon University Hospital, Athens, Greece; and Ospedale Maggiore Policlinico, Milan, Italy. The women were screened between February and September 2015 and gave written informed consent to participate in the study, which was approved by the National Health Service Research Ethics Committee in the UK and the Ethics Committee of each participating hospital in other countries. The results from screening were not made available to the patients or their physicians.
Maternal factors were recorded as described previously 4 and MAP and UtA-PI were measured using standardized protocols 7, 8 . Serum pregnancy-associated plasma protein-A (PAPP-A) and PlGF concentrations were measured by an automated device (PAPP-A and PlGF 1-2-3 TM kits, DELFIA ® Xpress random access platform; PerkinElmer Inc. Wallac Oy, Turku, Finland). Measured values of MAP, UtA-PI, PAPP-A and PlGF were expressed as multiples of the median, adjusting for those characteristics found to provide a substantive contribution to the log 10 -transformed value, including maternal factors, in the prior model [9] [10] [11] [12] . The outcome measure was PE, as defined by the International Society for the Study of Hypertension in Pregnancy 13 . Data on pregnancy outcome were collected from the hospital maternity records of the women. The obstetric records of all women with pre-existing or pregnancy-associated hypertension were examined to determine if the condition was PE.
The FMF algorithm was used for the calculation of patient-specific risks of delivery with PE delivering < 32, < 37 and ≥ 37 weeks' gestation using maternal factors and various combinations of maternal factors and biomarkers 4, 5 . DR, with 95% CI, at a FPR of 10% was estimated. Similarly, the maternal characteristics and medical history of each patient were examined to determine whether they were screen positive or negative according to the NICE 1 and ACOG 2,3 guidelines; the DR, with 95% CI, of delivery with PE delivering < 32, < 37 and ≥ 37 weeks' gestation and the FPR were then estimated.
The statistical software package R was used for data analyses 14 .
RESULTS
In the study population, 239 (2.7%) cases developed PE, of which 17 (0.2%), 59 (0.7%) and 180 (2.1%) developed PE < 32, < 37 and ≥ 37 weeks, respectively, and 8536 cases were without PE. Baseline demographic and clinical characteristics of participants are shown in Table S1 .
The performance of screening by the FMF algorithm 4,5 and the methods advocated by NICE 1 and ACOG 2, 3 are summarized in Table 1 . Combined screening by maternal factors, MAP, UtA-PI and PlGF 4,5 detected 100% (95% CI, 80-100%) of PE < 32 weeks, 75% (95% CI, 62-85%) of PE < 37 weeks and 43% (95% CI, 35-50%) of PE ≥ 37 weeks, at a 10.0% FPR. The receiver-operating characteristics curves are shown in Figure 1 . Screening with use of NICE guidelines 1 detected 41% (95% CI, 18-67%) of PE < 32 weeks, 39% (95% CI, 27-53%) of PE < 37 weeks and 34% (95% CI, 27-41%) of PE ≥ 37 weeks, at a 10.2% FPR. Screening with use of ACOG recommendations 2 detected 94% (95% CI, 71-100%) of PE < 32 weeks, 90% (95% CI, 79-96%) of PE < 37 weeks and 89% (95% CI, 84-94%) of PE ≥ 37 weeks, at a 64.2% FPR. The results of the methods advocated by NICE 1 and ACOG 2,3 are illustrated in Figure 1 . Screening based on the ACOG recommendations for use of aspirin 3 detected 6% (95% CI, 1-27%; 1/17) of PE < 32 weeks, 5% (95% CI, 2-14%; 3/59) of PE < 37 weeks and 2% (95% CI, 0.3-5%; 3/180) of PE ≥ 37 weeks, at a 0.2% (19/8536) FPR.
DISCUSSION

Main findings
The findings of this prospective multicenter validation study demonstrate that the performance of first-trimester screening for PE by the FMF algorithm, in which the patient-specific risk is derived from a combination of maternal factors, MAP, UtA-PI and PlGF 4, 5 , is by far superior to the methods advocated by NICE 1 and ACOG 2, 3 . In screening by the FMF algorithm, the DRs of delivery with PE < 32, < 37 and ≥ 37 weeks' gestation were 100%, 75% and 43%, respectively, at a FPR of 10.0%. The respective DRs in screening according to NICE guidelines 1 were 41%, 39% and 34%, at a FPR of 10.2%. In the case of ACOG recommendations 2 , about two-thirds of the population were classified as screen positive; the DRs of delivery with PE < 32, < 37 and ≥ 37 weeks were 94%, 90% and 89%, respectively, at a FPR of 64.2%. In screening based on the ACOG recommendations for use of aspirin 3 , the DRs of delivery with PE < 32, < 37 and ≥ 37 weeks were 6%, 5% and 2%, respectively, at a FPR of 0.2%.
Study limitations
The main limitation of the study relates to the low incidence of delivery with PE with the inevitable wide confidence intervals obtained for performance of screening. Nevertheless, the values obtained in the validation study are very similar to those in the dataset of 35 948 pregnancies that was used for development of the algorithm 5 . Table 1 Detection rate of pre-eclampsia (PE) delivering < 32, < 37 or ≥ 37 weeks' gestation in validation dataset using screening algorithm developed by The Fetal Medicine Foundation (FMF) 5 based on maternal factors and combinations of biomarkers, and using recommendations of National Institute of Health and Care Excellence (NICE) 1 Values in parentheses are 95% CI. DR, detection rate; FPR, false-positive rate; MAP, mean arterial pressure; PAPP-A, pregnancy-associated plasma protein-A; PlGF, placental growth factor; UtA-PI, uterine artery pulsatility index. 
Figure 1
Receiver-operating characteristics curves for prediction of delivery with pre-eclampsia at < 32 weeks (a), < 37 weeks (b) and ≥ 37 weeks (c) of gestation using The Fetal Medicine Foundation algorithm, combining maternal factors, mean arterial pressure, uterine artery pulsatility index and placental growth factor. Performance of screening using the methods of National Institute for Health and Care Excellence (NICE) 1 , American College of Obstetricians and Gynecologists (ACOG) 2 and ACOG for use of aspirin 3 are shown.
Implications for practice
In a proposed new pyramid of pregnancy care 15 , assessment of risk at 11-13 weeks' gestation aims to identify pregnancies at high risk of developing PE and, through pharmacological intervention with such medications as low-dose aspirin, reduce the incidence of these complications [16] [17] [18] . Administration of low-dose aspirin from the first-trimester to those at high risk is effective in prevention of preterm, rather than term, PE 18 , and the use of the method advocated by the FMF 4,5 is superior to those recommended by NICE 1 and ACOG 2,3 in identifying the group of pregnancies that could benefit from such therapy. According to FMF and NICE, about 10% of the pregnant population would receive low-dose aspirin and this population would contain 75% of those that will develop preterm PE if selection of the high-risk group was based on the FMF algorithm and only 39% if selection was based on the NICE guidelines. In the case of the ACOG recommendations, 0.2% of the population would receive aspirin and only 5% of cases of preterm PE that would potentially benefit from such therapy would be targeted.
The methods of NICE 1 and ACOG 2 treat each maternal factor as a separate screening test with additive DR and FPR. In the FMF method, use of a multivariable logistic model to define the prior risk attributes the appropriate relative importance to each maternal factor and allows estimation of the patient-specific risk of PE requiring delivery before a specified gestation 4 . The prior risk can then be adjusted according to the results of biophysical and biochemical testing 5 . The software for such estimation of prior and adjusted risk is freely available (www.fetalmedicine.com). Recording of maternal history and measurement of blood pressure are universally carried out as part of routine pregnancy care; measurement of MAP requires adherence to a protocol 7 but can be undertaken by healthcare assistants after minimal training, using inexpensive equipment and taking a few minutes to perform. Measurement of UtA-PI requires specific training by sonographers and quality assurance of their results 8 ; nevertheless, this test can be undertaken within a few minutes by the same sonographer and machine as part of the routine first-trimester scan. Measurement of serum PlGF can be undertaken on the same machine as free β-human chorionic gonadotropin and PAPP-A, which are widely used in screening for Down syndrome.
Cribado multicéntrico de preeclampsia a partir de factores maternos y biomarcadores a las 11-13 semanas de gestación: comparación con las directrices de NICE y las recomendaciones de ACOG RESUMEN Objetivo Comparar el desempeño del cribado de preeclampsia (PE) a partir de factores de riesgo del historial clínico, siguiendo las recomendaciones de NICE y ACOG, con el método propuesto por The Fetal Medicine Foundation (FMF), que utiliza el teorema de Bayes para combinar el riesgo a priori de los factores maternos, estimado en función de un modelo logístico multivariable, con los resultados de diversas combinaciones de medidas biofísicas y bioquímicas.
Métodos La investigación fue un estudio multicéntrico prospectivo del cribado de PE en 8775 embarazos con fetoúnico a las 11-13 semanas de gestación. Se utilizó un algoritmo ya publicado por la FMF para el cálculo del riesgo específico de PE para cada paciente. Se estimaron las tasas de detección (TD) y las tasas de falsos positivos (TFP) para el parto con PE <32, <37 y ≥37 semanas y se compararon con las tasas obtenidas mediante la aplicación de las directrices de NICE y las recomendaciones de ACOG. Según NICE, todos los embarazos de alto riesgo deberían recibir una dosis baja de aspirina. De acuerdo con ACOG, el uso de aspirina se debería reservar para las mujeres con antecedentes de PE en al menos dos embarazos previos o PE que requiere inducción del parto a <34 semanas de gestación.
